Navigation Links
Recently Patented Technology Poised To Disrupt The Plasma Biopharmaceutical Market
Date:9/10/2013

CHARLESTON, S.C., Sept. 10, 2013 /PRNewswire/ -- Plasma Technologies LLC, a plasma biologics technology company, announced the recent issuance of US patent #8,293,242, an "Ultra-High Yield of Alpha-1 Antitrypsin" and the Company's plans to commercialize its patented extraction process for plasma biologics. The Company's technology fundamentally changes the economics of blood plasma fractionation by substantially increasing the yield of alpha-1 antitrypsin (AAT) and intravenous immune globulin (IVIG) and makes possible the extraction of several additional therapeutically useful plasma proteins.  The non-denaturing process will enable plasma-derived biologics to be differentiated on the basis of improved molecular integrity that will enhance patient tolerance, will minimize the danger of thromboembolic events and will preserve the serum half-lives of the biomolecules.

The existing $15 Billion worldwide plasma biologics market is substantially underserved, and continues to grow at about 10% annually. Driving that growth is the demand for AAT, used to treat a growing number of diseases. AAT deficiency is a genetic condition resulting in damage to lung, liver, and pancreatic tissues, with pulmonary emphysema as the most common indication. In North America and Europe there at least 150,000 people living with AAT deficiency, but fewer than 10,000 receive AAT therapy, which is lifelong and involves weekly injections of AAT. Administration of AAT in non-deficient individuals may interfere with disease progression in the following conditions:  Diabetes (type 1 & 2), acute myocardial infarction, inflammatory bowel disease, cystic fibrosis, graft vs. host disease, stroke, Alzheimer's disease, vasculitis, organ transplantation, and multiple sclerosis.

Current methods of AAT production cannot meet the demand created by the expanding number of clinical indications. Plasma Technologies LLC believes that AAT can be supplied in volumes needed to meet current and future demand through the adoption by pharmaceutical manufacturers of the Company's proprietary extraction process, the elements of which are salt precipitation from plasma, subsequent salt removal by diafiltration and final purification by means of affinity and ion exchange chromatography. Increased supply of AAT will be complemented by new low-cost genetic tests that identify patients likely to benefit from AAT therapy.

The Company's process and technology are covered by US Patents #7,879,331, #7,879,332, and #8,293,242, the last of which will not expire until November 2030.  Patents have also been filed in major patent jurisdictions outside the United States.

Additional information about the Company and its technology can be found on its website at www.plasmatechnologies.us


'/>"/>
SOURCE Plasma Technologies LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. The Alliance for the Advancement of Adult Stem Cell Therapy and Research Recently Has Proven Stem Cells To Be Effective in Dilated Cardiomyopathy
2. SoundConnect Recently Selected by iCIMS, Inc.
3. Recently FDA-Approved Full Neck Treatment for Sagging Skin Now Available at Maryland Laser Skin and Vein Institute
4. Recently Published Economic Analysis Highlights the Financial Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) in the United States (US)
5. DryLet Technologies Announces the Rebranding and Launch of Patented ManureMagic™
6. DryLet Technologies Announces Website Launch and New Logo Design for Patented MB Bioremediation
7. Dr. Rongxiang Xu, Owner of Patented Technology to Regenerate Damaged Organs, Announces Lawsuit Against 2012 Nobel Laureate Dr. Shinya Yamanaka
8. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
9. CannaBANK Acquires Rights to License PharmaSpheres Patented Growth System
10. Riordan Clinic Research Institute Has Developed and Patented a Process for the Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome
11. Netswitch Technology Management Ranks in Top 100 Cloud and Managed Service Providers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):